Revive Therapeutics Ltd., a Canadian health care company operating within the pharmaceutical sector, has recently garnered attention for its innovative approach to cannabinoid-based product development. Listed on the Canadian National Stock Exchange, the company has been making strides in the health care industry, particularly with its focus on addressing acute gout flares through its flagship product, REV-002.
As of March 16, 2026, Revive Therapeutics Ltd. reported a close price of 0.07 CAD, with its stock experiencing a 52-week high of 0.08 CAD and a low of 0.005 CAD on December 2, 2025. The company’s market capitalization stands at 25,939,428 CAD, reflecting its growing presence in the market.
A significant milestone for Revive Therapeutics Ltd. has been the successful completion of Phase II-A clinical studies for REV-002, a bucillamine-based treatment. This development marks a crucial step forward in the company’s mission to provide effective solutions for patients suffering from acute gout flares. The completion of these clinical studies not only underscores the company’s commitment to innovation but also highlights its potential to impact the pharmaceutical landscape positively.
Revive Therapeutics Ltd. continues to focus on the development and commercialization of cannabinoid-based products, leveraging the therapeutic potential of cannabinoids to address various health conditions. The company’s dedication to research and development is evident in its strategic approach to bringing new treatments to market, with REV-002 being a prime example of its efforts.
For those interested in learning more about Revive Therapeutics Ltd. and its offerings, additional information is available on their website, www.revivethera.com . As the company progresses with its clinical studies and product development, it remains a noteworthy entity in the health care sector, particularly within the realm of cannabinoid-based therapies.
In summary, Revive Therapeutics Ltd. is poised to make significant contributions to the pharmaceutical industry, with its innovative approach to treating acute gout flares through REV-002. As the company continues to advance its research and development initiatives, it holds promise for delivering impactful health care solutions to patients in need.
